# Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

> **NCT00312975** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 90 (actual)

## Conditions studied

- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** CP-675,206
- **DRUG:** best supportive care

## Key facts

- **NCT ID:** NCT00312975
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-04
- **Final completion:** 2010-02
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312975, "Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00312975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*